Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 18 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

0%

0 of 12 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
15(93.8%)
Phase 3
1(6.3%)
16Total
N/A(15)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT07539051Not Yet Recruiting

Psychoemotional Status and Functional Gastrointestinal Disorders

Role: lead

NCT07501858Recruiting

Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metabolic Syndrome

Role: lead

NCT06434077Phase 3Not Yet Recruiting

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Role: collaborator

NCT06264570Not ApplicableRecruiting

Evaluation of a Genetically Determined Personalized Approach in Prescribing Biologically Active Substances in Patients With Elevated Blood Homocysteine Levels.

Role: collaborator

NCT06264544Not ApplicableNot Yet Recruiting

Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism

Role: collaborator

NCT06470425Not ApplicableCompleted

Optimizing Mental Health Management With AI-Guided (GenAIS TM) Dietary Supplementation

Role: collaborator

NCT06470412Not ApplicableCompleted

Personalized Management of Autoimmune Diseases With AI-Guided (GenAIS TM) Dietary Supplementation

Role: collaborator

NCT06188832Not ApplicableCompleted

Efficacy of Dietary Fiber Supplementation (Soloways) in Patients With Specific Genetic Polymorphisms

Role: collaborator

NCT06163443Not ApplicableCompleted

Evaluating the Impact of B Vitamin Supplementation (Soloways™) on Homocysteine and LDL-C Levels in Patients With MTHFR, MTR, and MTRR Polymorphisms.

Role: collaborator

NCT06313164Not ApplicableCompleted

The Impact of Oral Glutathione on Oxidative Damage and Glycated Hemoglobin (HbA1c) Levels in Type 2 Diabetes Patients

Role: collaborator

NCT06154408Not ApplicableCompleted

Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms

Role: collaborator

NCT06469658Not ApplicableCompleted

Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation

Role: collaborator

NCT06458296Not ApplicableCompleted

Evaluating the Efficacy of AI-Guided (GenAIS TM) vs. Standard Physician-Guided Dietary Supplement Prescriptions for Weight Loss in Obese Patients

Role: collaborator

NCT06448234Not ApplicableCompleted

Evaluating the Efficacy of AI-Guided (GenAIS TM) vs. Standard Physician-Guided Dietary Supplement Prescriptions for Lowering LDL Cholesterol in Hypercholesterolemic Patients

Role: collaborator

NCT06357936Not ApplicableNot Yet Recruiting

Nanofat Grafting as a Method of Treating Critical Limb Ischemia

Role: lead

NCT06328348Not ApplicableCompleted

Assessing the Synergistic Effects of Black Cohosh, Soy Isoflavones, and SDG Lignans (Soloways TM) on Menopausal Symptoms

Role: collaborator

NCT06221696Not ApplicableCompleted

Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)

Role: collaborator

NCT06215196Not ApplicableCompleted

Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity

Role: collaborator

All 18 trials loaded